☆ 4.3 Letter

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

LEUKEMIA & LYMPHOMA (2016)

Get Full Text
Add to Collection

Journal

LEUKEMIA & LYMPHOMA
Volume 57, Issue 6, Pages 1463-1466

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2015.1091927

Keywords

-

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.